Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Mantle-Cell

Explore clinical trials studying Lymphoma, Mantle-Cell. Study availability and eligibility vary by location and protocol.

889 public trials 111 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Mantle-Cell trial results

Completed

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

NCT04716075

Conditions
Adverse Event, Bronchial Diseases, Bronchiolitis, +33 more
Locations
  • Szpital Kliniczny Przemienienia Pańskiego, Oddział Hematologii i Transplantacji Szpiku Poznan, Greater Poland Voivodeship, Poland
  • Instytut Hematologii i Transfuzjologii Warsaw, Masovian Voivodeship, Poland
  • Narodowy Intytut Onkologii im. M. Skłodowskiej-Curie Oddział w Krakowie, Pododdział Leczenia Nowotworów Układu Chłonnego Krakow, Małopolska, Poland
  • Klinika Transplantacji Szpiku i Onkohematologii; Centrum Onkologii Instytut im. M.Sklodowskiej-Curie, Oddz. w Gliwicach Gliwice, Silesian Voivodeship, Poland
View Trial Details
Completed

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968

Conditions
Adnexal Diseases, Blood Protein Disorders, Breast Cancer, +68 more
Locations
  • University of California San Francisco San Francisco, California, United States
  • Stanford Comprehensive Cancer Center Stanford, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists and Research Institute Sarasota, Florida, United States
View all 16 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details
Completed

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05008055

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Houston, Texas, United States
  • Research Site Victoria, British Columbia, Canada
View all 17 locations
View Trial Details
Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

NCT04930536

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma, Disease Attributes, +18 more
Locations
  • Research Site Ahmedabad, India
  • Research Site Bangalore, India
  • Research Site Bangalore, India
  • Research Site Bengaluru, India
View all 15 locations
View Trial Details
Completed

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

NCT02268851

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +18 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • St. Francis Hospital and Cancer Center Hartford, Connecticut, United States
  • Eastern Maine Medical Center/ Northern Light Cancer Care Brewer, Maine, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402

Conditions
B-Cell Non-Hodgkins Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +50 more
Locations
  • Moores UC San Diego Cancer Center La Jolla, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • Northside Hospital Atlanta, Georgia, United States
  • The University of Chicago Medicine Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT03206970

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View all 13 locations
View Trial Details

Related conditions